miir partners with International Biosciences to develop potential drugs against cancer -
announced the Marshall Institute for Interdisciplinary Research (MIIR) and Joan C. Edwards Marshall University School of medicine today they will partner with an international company Biosciences to develop potential drugs against cancer.
under agreement with Shanghai HD Biosciences Co. Ltd., the three partners will share the costs and risks of discovery and development of these new drugs. They will also jointly own all intellectual property and product marketing rights resulting from the collaboration.
According to Dr. Zijian Xie, director of MIIR, of new drugs research laboratory in which tests clinical, it is determined whether the treatment is safe and effective for humans-is a costly and takes time.
"Normally it would take tens of millions of dollars and as long as a decade to translate MIIR of Technology and School of Medicine has developed in recent years in drugs viable candidates, "he said. "This joint effort with HD Biosciences will reduce significantly the process because of their expertise in drug discovery, and ultimately will reduce the risk for all partners.
"In short, this is a bold approach that will not only advance the mission of MIIR innovation, discovery, business and promotion, but also to create new business opportunities and add value to all of us. "
Dr. Joseph I. Shapiro, dean of the medical school, said the partnership was formed in order to bring new treatments for patients of cancer as soon as possible.
"We could not be happier to work with HD Biosciences. Our company allows scientists based laboratory and clinical researchers to share ideas, to advance at a faster pace and ultimately offer better patient care, "he said
Dr. Xuehai Tan, President and CEO of HD Biosciences, added." We are very pleased to have established this collaboration with Marshall University. this agreement is another example of the strategy and the commitment of our company for long term growth. We will contribute with our extensive capabilities in preclinical drug discovery and drug development in the Chinese market, and our ability to create value for the company and our partners, while the university is well versed in translational medicine, clinical trials and US Food and drug administration Principles ".
Dr. John Maher, vice president for research Marshall said the company has a significant economic development potential for Marshall and the whole region.
He added, "working together to examine the commercial viability targets and treatments for diseases being developed to MIIR and medical school, we will be able to accelerate the translation search our discoveries in laboratories that will both help improve human health and to stimulate economic development in the region. "
EmoticonEmoticon